World News: 13:30 GMT Wednesday 12th June 2019. [Bionano Genomics via Globe Newswire via SPi World News]
SAN DIEGO, June 12, 2019 (GLOBE NEWSWIRE) -- . (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced the appointment of Kristiina Vuori, MD, PhD, to its board of directors. Dr. Vuori is President and member of the board of directors of the Sanford Burnham Prebys Medical Discovery Institute (SBP) where she also holds the Pauline and Stanley Foster Presidential Chair and serves as Professor at the National Cancer Institute (NCI)-designated Cancer Center at SBP. SBP is one of the largest non-profit biomedical research institutes in the U.S., with focus on cancer, neurodegeneration, inflammatory diseases, heart disease and rare children’s disorders.
“We are thrilled to welcome Dr. Vuori to our board of directors,” said Erik Holmlin, PhD, CEO of Bionano. “Dr. Vuori is an exceptional scientist and leader who has driven cutting-edge research to further advance our fundamental understanding of cancer and translate that understanding into actionable solutions in the clinic. Our Saphyr system has been developed to enable novel discoveries in oncology and human genetics that we anticipate will enable precision medicine. We believe that Dr. Vuori’s experience in biomedical research and translational medicine and her experience leading a large non-profit research organization will be invaluable for helping us drive toward this vision.”
Dr. Vuori commented, “It is with great enthusiasm that I join the Bionano Genomics Board of Directors. Bionano has powerful technology and strong leaders both in management and on the board. I look forward to working with all of them to advance the adoption of the Saphyr system and Bionano’s objective of making it an essential part of cancer research and clinical diagnostics.”
Dr. Vuori is recognized for delineating molecular pathways that regulate cancer cell survival, motility, metastasis and drug responsiveness. Her molecular characterization of prolyl hydroxylase (PH) helped to enable the formation of FibroGen. Dr. Vuori has published more than 100 research papers in leading scientific journals, and received numerous research grants and awards from NIH, NCI, DoD, Stand Up To Cancer Dream Team, and the California Cancer Research Programs. She was selected as a PEW Scholar in the Biomedical Sciences in 1997 and elected to the National Academy of Inventors in 2014. Dr. Vuori earned her MD and PhD degrees at University of Oulu, Finland. After completing her internship and residency, she received postdoctoral training at Sanford-Burnham from 1992 to 1995 and was appointed to the faculty in 1996.
Globe Newswire: 13:30 GMT Wednesday 12th June 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.